Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Teva Pharmaceutical Industries Limited (TEVA)

NYQ · Drug Manufacturers - Specialty & Generic

$31.67+0.59 (+1.90%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$36.88B
P/E (TTM)
23.29
EPS
$1.36
Div Yield
52W Range
$14.99–$37.35
Beta
0.86

Company overview

Next earnings: 2026-07-29(1d)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Peers in Drug Manufacturers - Specialty & Generic

All in industry →

Recent press releases

Teva Pharmaceutical Industries Limited has not issued a press release in this window.

SEC filings

All filings →

Teva Pharmaceutical Industries Limited has not filed an SEC document in this window.

Teva Pharmaceutical Industries Limited has no reported insider trades in the last 90 days.

Institutional holders

All holders →

No 13F holdings have been reported for Teva Pharmaceutical Industries Limited in this window.

People at Teva Pharmaceutical Industries Limited

All people →

Quarterly financials

Full financials →

No quarterly financials have been ingested for Teva Pharmaceutical Industries Limited.

TEVA (NYQ) Stock Quote, Press Releases & SEC... | Cayman Journal | Cayman Journal